• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Prescription Heroin, Joy of Cooking, Health Care Spending

By
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Down Arrow Button Icon
December 6, 2018, 6:41 PM ET

Just how bad is America’s epidemic of opioid painkiller (legal and illicit alike) addiction and overdose epidemic? A new expert analysis from the RAND Corporation suggests that prescribing heroin (yes, that heroin) could be an effective tool for combating the crisis in extreme circumstances.

“Given the increasing number of deaths associated with fentanyl and successful use of heroin-assisted treatment abroad, the U.S. should pilot and study this approach in some cities,” says Beau Kilmer, co-director of the RAND Drug Policy Research Center, in a statement. “This is not a silver bullet or first-line treatment. But there is evidence that it helps stabilize the lives of some people who use heroin.”

To be clear, the RAND analysis focuses on individuals who have severe opioid addiction – those whose disease isn’t effectively treated by the traditional methods, such as conventional medication assisted therapy and rehab through the use of products such as methadone and buprenorphine.

But the study authors point out that some of the highest-risk patients still wind up injecting illegal street opioids while undergoing treatment with those substances, substantially raising their risk of overdose death. For these people, “heroin-assisted treatment” may prove an effective, if controversial, measure, especially since prescription grade heroin is far less likely to harbor contaminants or be cut with other dangerous chemicals.

Whether or not such initiatives would be widely adopted is another question. Clean needle exchange programs for drug users and “safe injection sites” have been matters of serious controversy, and they don’t involve directly providing heroin to users.

Whatever your viewpoint, RAND’s entire analysis is worth reading in full.

Read on for the day’s news.

Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

DIGITAL HEALTH

Have the new Apple Watch? You can take an ECG now. The Apple Watch Series 4's much-ballyhooed electrocardiogram (ECG) heart monitoring feature is officially live today, the company announced. That includes the activation of notifications that can warn users of irregular heart rhythms (if you happen to own one of the devices and are interested in checking the feature out, Apple has a guide in its press release). “We are confident in the ability of these features to help users have more informed conversations with their physicians,” said Apple Health VP Sumbul Desai in a statement. While the ECG feature is a milestone for mass market wearables, some critics have raised concerns that it could lead to unnecessary medical care through potential false positives. Apple insists the product shouldn't be regarded as a full-on medical device, but rather a tool that can guide discussions with physicians.

INDICATIONS

How do you solve a problem like CAR-T prices? BioPharma Dive has an excellent dispatch from the American Society of Hematology meeting in San Diego on the struggles doctors and hospitals have grappling with the exorbitant prices of new cancer technologies like CAR-T (the new treatments from companies like Novartis and Gilead which re-engineer patients' own immune cells to become targeted cancer hunters). Extracting, modifying, replicating, and then re-inserting immune cells through this process is, unsurprisingly, expensive. And regulators are still trying to figure out the best way to assess the value on such therapies while still providing patients access (and the innovators behind the technology their fair share). Here's what one doctor had to say the ASH conference: "None of us imagined we'd be ... reading through 1,000-page-long [Centers for Medicare & Medicaid Services] documents and rules and proposals, but that's what life has come to at times." (BioPharma Dive)

THE BIG PICTURE

U.S. health care spending growth slows. The federal government projects that growth in U.S. health care spending (that is, a measure of medical inflation) remained modest in 2017, rising 3.9% to $3.5 trillion. That was due to relatively low spending increases in hospital care and retail prescription drugs, according to the Centers for Medicare & Medicaid Services. However, the same agency has projected that 2018 health care spending will spike 5.3%. (Reuters)

The joy of retractions. Food researcher Brian Wansink's (in)famous study on the ostensible unhealthiness of recipes in the popular Joy of Cooking cookbook has been retracted by the Annals of Internal Medicine, which cites problems with the data presented as part of the research. Wansink says the cited issues are relatively minor; but this isn't the first study of his to be retracted over data validity concerns. (Associated Press)

REQUIRED READING

Commentary: It's Time to Nix the Two Week Pay Cycle, by Steve Barha

Why Huawei CFO's Arrest Has Helped Send Stock Markets Into a Tailspin, by David Meyer

California Becomes First State to Require Solar Panels on New Homes, by Natasha Bach

Nearly All Major Economies Will Face a Slowdown Next Year, by Rey Mashayekhi

Produced by Sy Mukherjee
@the_sy_guy
sayak.mukherjee@fortune.com

Find past coverage. Sign up for other Fortunenewsletters.
About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
14 hours ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
2 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
2 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
3 days ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
3 days ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
3 days ago

Most Popular

placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
20 hours ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
22 hours ago
placeholder alt text
Success
Sorry, six-figure earners: Elon Musk says that money will 'disappear' in the future as AI makes work (and salaries) irrelevant
By Orianna Rosa RoyleDecember 15, 2025
23 hours ago
placeholder alt text
AI
Deloitte's CTO on a stunning AI transformation stat: Companies are spending 93% on tech and only 7% on people
By Nick LichtenbergDecember 15, 2025
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, December 15, 2025
By Joseph HostetlerDecember 15, 2025
24 hours ago
placeholder alt text
North America
Ford writes down $19.5 billion as it pivots electric Lighting line of vehicles
By Sasha RogelbergDecember 15, 2025
16 hours ago